TEM basically mixes genomic and clinical data with AI. This is at the core of their new offerings for precision diagnostics ...

Ares Management Corporation (NYSE: ARES) ("Ares"), a leading global alternative investment manager, announced today that Ares Credit funds served as the administrative agent on $300 million in ...

The local sector of test makers, specialized equipment manufacturers and testing product suppliers remain invested in their ...

There's still plenty of time for growth investors to click the buy button on Tempus AI stock; however, it's critical to ...

We recently published a list of Top 10 AI Stocks Trending On Wall Street. In this article, we are going to take a look at ...

Tempus AI has delivered an 82% YTD return, outperforming the broader market and AI-themed stocks amidst market volatility.

Investing.com -- TD Cowen reinstated coverage on Tempus AI with a "Buy" rating and raised its price target to $74 after the ...

Up about 12%, Tempus AI (NASDAQ:TEM) has been explosive. Helping, its volume just spiked to 18.6 million shares, as compared ...

Tempus AI (TEM) is soaring 13% today after investment bank TD Cowen reinstated coverage of the shares with a Buy rating. TEM ...

One, Tempus AI just acquired Ambry Genetics. Two, Nancy Pelosi and Cathie Wood are bullish on Tempus AI. Three, TD Cowen just upgraded the TEM stock to a buy with a $74 price target. If you’re ...

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care ...

All thanks to three key catalysts. Tempus AI just acquired Ambry Genetics, a well-known leader in genetic testing, for $600 million, which includes $375 million in cash payments and $225 million ...